Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD) (ACES 257)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01123707
Recruitment Status : Terminated
First Posted : May 14, 2010
Last Update Posted : August 31, 2012
Information provided by (Responsible Party):
Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary:
This will be a multicenter, 52-week, open-label study designed to assess the safety and tolerability of an oral aripiprazole/escitalopram combination therapy in outpatients with major depressive disorder (MDD). Enrollment into the study will be from eligible subjects who have completed participation in Protocol 31-08-255, 31-08-256, or 31-08-263 ("rollover" subjects).

Condition or disease Intervention/treatment Phase
Major Depressive Disorder (MDD) Drug: Aripiprazole/Escitalopram combination therapy Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 170 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, 52-week, Open-label Study to Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Study Start Date : November 2010
Actual Primary Completion Date : July 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Aripiprazole/Escitalopram combination therapy Drug: Aripiprazole/Escitalopram combination therapy
Aripiprazole/Escitalopram combination therapy: 3 mg/10 mg, 3 mg/20 mg, 6 mg/10 mg, 6 mg/20 mg, 12 mg/10 mg or 12 mg/20 mg

Primary Outcome Measures :
  1. Safety - based on the frequency and severity of AEs & SAEs [ Time Frame: 1 year ]

    The primary evaluation of safety will be through frequency and severity of adverse events (AEs), including serious AEs (SAEs), and discontinuations due to AEs.

    In addition to AEs, safety variables examined in this study will include physical exams, vital signs, body weight, body mass index, clinical laboratory tests, electrocardiograms, the Abnormal Involuntary Movement Scale (AIMS), the Simpson Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), the Columbia-Suicide Severity Rating Scale (C-SSRS), and the Massachusetts General Hospital Sexual Functioning Inventory (MGH SFI).

Secondary Outcome Measures :
  1. Efficacy [ Time Frame: 1 year ]

    Evaluation of efficacy will include the Clinical Global Impressions Severity of Illness Scale (CGI-S) and the Patient Global Impressions of Severity Scale (PGI-S).

    Outcome: The Sheehan Disability Scale (SDS), the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q - Short Form), and the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ). Responses to the Resource Utilization Form will be summarized appropriately to explore the impact of treatment on health care resources.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 66 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects who participated in Protocol 31-08-255, 31-08-256, or 31-08-263.

Exclusion Criteria:

  • Subjects with a current need for involuntary commitment or who have been hospitalized ≤ 28 days of the Baseline Visit for the current major depressive episode.
  • Subjects with a diagnosis of delirium, dementia, amnestic or other cognitive disorder, schizophrenia, schizoaffective disorder, or other psychotic disorder, Bipolar I or II disorder, Eating disorder (including anorexia nervosa or bulimia), obsessive compulsive disorder, panic disorder, or posttraumatic stress disorder.
  • Subjects with a diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder.
  • Subjects experiencing hallucinations, delusions, or any psychotic symptomatology in the current depressive episode.
  • Subjects who have met DSM-IV-TR criteria for substance abuse in the past 6 months (prior to the Baseline Visit) and/or dependence up to and including the past 12 months (prior to the Baseline Visit), including alcohol and benzodiazepines, but excluding caffeine and nicotine. Subjects with two positive drug results for cocaine should be excluded from the study.
  • Subjects with hypothyroidism or hyperthyroidism.
  • Subjects with a significant risk of committing suicide based on history, investigator's judgment, and/or evaluation based on the C-SSRS
  • Subjects who currently have clinically significant neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, or gastrointestinal disorders.
  • Subjects with insulin-dependent diabetes mellitus (IDDM).
  • Subjects with epilepsy or significant history of seizure disorders, except for a single childhood febrile seizure, post-traumatic, etc.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01123707

Hide Hide 62 study locations
Layout table for location information
United States, Alabama
Birmingham, Alabama, United States, 35216
United States, Arizona
Tucson, Arizona, United States, 85710
United States, Arkansas
Little Rock, Arkansas, United States, 72223
United States, California
Cerritos, California, United States, 90703
Chino, California, United States, 91710
Costa Mesa, California, United States, 92626
Garden Grove, California, United States, 95231
Imperial, California, United States, 92251
Irvine, California, United States, 92618
Mission Viejo, California, United States, 92691
Redlands, California, United States, 92374
Riverside, California, United States, 92506
San Diego, California, United States, 92102
San Diego, California, United States, 92128
Santa Ana, California, United States, 92705
Torrance, California, United States, 90502
United States, Colorado
Denver, Colorado, United States, 80204
United States, Connecticut
Cromwell, Connecticut, United States, 06416
United States, Florida
Fort Walton Beach, Florida, United States, 32547
Gainesville, Florida, United States, 32607
United States, Georgia
Atlanta, Georgia, United States, 30308
Marietta, Georgia, United States, 30060
United States, Illinois
Hoffman Estates, Illinois, United States, 60169
Libertyville, Illinois, United States, 60048
United States, Indiana
Terre Haute, Indiana, United States, 47802
United States, Kansas
Overland Park, Kansas, United States, 66211
Prairie Village, Kansas, United States, 66206
Wichita, Kansas, United States, 67207
United States, Maryland
Baltimore, Maryland, United States, 21204
United States, Massachusetts
Belmont, Massachusetts, United States, 02478
Fall River, Massachusetts, United States, 02721
Weymouth, Massachusetts, United States, 02190
United States, Missouri
St. Louis, Missouri, United States, 63141
United States, New Mexico
Albuquerque, New Mexico, United States, 87109
United States, New York
Bronx, New York, United States, 10467
Brooklyn, New York, United States, 11235
Fresh Meadows, New York, United States, 11366
New York, New York, United States, 10021
Staten Island, New York, United States, 10305
United States, North Carolina
Cary, North Carolina, United States, 27518
United States, Ohio
Toledo, Ohio, United States, 43623
United States, Oklahoma
Oklahoma City, Oklahoma, United States, 73112
United States, Rhode Island
East Providence, Rhode Island, United States, 02914
United States, Tennessee
Bartlett, Tennessee, United States, 38134
Memphis, Tennessee, United States, 38119
United States, Texas
De Soto, Texas, United States, 75115
Wichita Falls, Texas, United States, 76309
United States, Washington
Kirkland, Washington, United States, 98033
United States, Wisconsin
Brown Deer, Wisconsin, United States, 53223
Australia, Queensland
Everton Park, Queensland, Australia, 4053
Jamejala, Estonia, 71024
Tartu, Estonia, 50406
Tartu, Estonia, 54507
Ostfildern, Germany, 73760
Ahmedabad, Gujarat, India, 380006
Catania, Italy, 95123
Siena, Italy, 53100
Korea, Republic of
Gwangju, Korea, Republic of, 501-75
Seoul, Korea, Republic of, 138-736
Seoul, Korea, Republic of, 139-872
Seoul, Korea, Republic of, 150-713
Mexico, DF, Mexico, 06700
Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.

Layout table for additonal information
Responsible Party: Otsuka Pharmaceutical Development & Commercialization, Inc. Identifier: NCT01123707    
Other Study ID Numbers: 31-08-257
First Posted: May 14, 2010    Key Record Dates
Last Update Posted: August 31, 2012
Last Verified: August 2012
Keywords provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:
Major Depressive Disorder
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depressive Disorder, Major
Pathologic Processes
Mood Disorders
Mental Disorders
Behavioral Symptoms
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Antipsychotic Agents